Current issues in biowaivers and biosimilars

Expert Review of Clinical Pharmacology

Volumn 6, Issue 2, 2013, Pages 139-142

  Endrenyi, Laszlo ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; BIOSIMILAR AGENT; BIOWAIVER AGENT; ENTEROTOXIN; MACROGOL; POVIDONE; TRASTUZUMAB; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; CHIMERA; CONFERENCE PAPER; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; FREEZE DRYING; GLYCOSYLATION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN EXPRESSION; PROTEIN UNFOLDING; SPRAY DRYING; VISCOSITY;

EID: 84874839971     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.72     Document Type: Conference Paper

References (17)

1. FDA. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. US Food and Drug Administration, MD, USA (2000
2. WHO. Multisource (Generic) Pharmaceutical Products: Guidelines on Registration Requirements to Establish Interchangeability; Chapter 9. World Health Organization, Geneva, Switzerland (2005
3. EMEA (European Medicines Agency). Guideline on Similar Medicinal Biological Products. Committee for Medicinal Products for Human Use, London, UK
4. WHO. Guidelines on Evaluation of Similar Biotherapeutic Products (SBPs). World Health Organization, Geneva, Switzerland
5. Health Canada. Guidance for Sponsors: Information and Submission Requirements for Subsequent Entry Biologics (SEBs
6. Health Products and Food Branch, ON, Canada (2010 BPCI Act. Biologics Price Competition and Innovation Act of 2009. Federal Register. H.R. 3590-686-702 (2010
7. FDA. Draft Guidance for Industry - Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, US Food and Drug Administration, MD, USA
8. FDA. Draft Guidance for Industry - Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, US Food and Drug Administration, MD, USA
9. FDA. Draft Guidance for Industry - Biosimilars: Questions and Answers Regarding Implementation of the Price Competition and Implementation Act of Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research, US Food and Drug Administration, MD, USA (2012
10. Amidon GL, Lennernäs H, Shah VP, Crison Jr. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12(3), 413-420 (1995
11. Epstein RA. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009. Food Drug Law J. 66, 285-328 (2011
12. Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals 5, 353-368 (2012
13. Endrenyi L, Chang C, Chow SC, Tothfalusi L. On the interchangeability of biologic drug products. Stat. Med. 32(3), 434-441. (2013
14. Bradley LH, Bricken ML, Randle C. Expression, purification, and characterization of proteins from high-.quality combinatorial libraries of the mammalian calmodulin central linker. Protein Expr. Purif. 75(2), 186-191 (2011
15. Hefferon KL. Plant virus expression vectors set the stage as production platforms for biopharmaceutical proteins. Virology (1), 1-6 (2012
16. Sauerborn M, Brinks V, Jiskoot W, Schellekens H. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol. Sci. 31(2), 53-59 (2010
17. Elkordy AA, Forbes RT, Barry BW. Study of protein conformational stability and integrity using calorimetry and FT-Raman spectroscopy correlated with enzymatic activity. Eur. J. Pharm. Sci. 33(2), 177-190 (2008